Immuron Ltd
IMM-529
Clostridioides difficile infection
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on IMM-529 for Clostridioides difficile infection is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 13h ago
“Anticipated IMM-529 FDA approval of IND in December 2025”